Gilead Sciences (GILD) Offering Possible 6.84% Return Over the Next 34 Calendar Days

This article was originally published on this site

Gilead Sciences’s most recent trend suggests a bearish bias. One trading opportunity on Gilead Sciences is a Bear Call Spread using a strike $67.50 short call and a strike $72.50 long call offers a potential 6.84% return on risk over the next 34 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $67.50 by expiration. The full premium credit of $0.32 would be kept by the premium seller. The risk of $4.68 would be incurred if the stock rose above the $72.50 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Gilead Sciences is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Gilead Sciences is bearish.

The RSI indicator is at 30.81 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Gilead Sciences

Frozen assets: How a startup wants to cryobank your cells to fight cancer in the future
Thu, 15 Aug 2019 21:27:26 +0000
The Florida startup has Bay Area investors and is aiming straight at people willing to pay thousands of dollars to beat cancer in the future.

European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis
Thu, 15 Aug 2019 20:01:00 +0000
Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis (RA) has been validated and is now under evaluation by the European Medicines Agency (EMA). “We are excited about the validation of this application which is an important milestone in our ongoing work to improve the lives of people living with rheumatoid arthritis and other inflammatory conditions,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences. The MAA for filgotinib is supported by 24-week data from the Phase 3 FINCH clinical trials in which once-daily treatment with filgotinib achieved improvements in clinical signs and symptoms, achievement of low disease activity and remission, and inhibition of structural damage for different sub-populations of patients living with RA.

Québec Provides Access to Biktarvy® for the Treatment of HIV
Thu, 15 Aug 2019 12:00:00 +0000
Québec Provides Access to Biktarvy® for the Treatment of HIV

Biotech Stock Roundup: Amgen’s Enbrel Patent Win, AMRN’s Setback & More
Wed, 14 Aug 2019 13:21:01 +0000
Key highlights of the past week include collaborations, and other regulatory and pipeline news.

Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
Wed, 14 Aug 2019 12:34:12 +0000
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals

Be Sociable, Share!

Related Posts